MOMatilde Oliveira

Matilde Oliveira

*This is an algorithmically generated author record based on publicly available information.

Matilde Oliveira has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Analgesic Effect of Methocarbamol: A Systematic Review

    by Carolina Damas Pereira, Gonçalo Silva, Beatriz Sousa, Carolina Portela, Carolina Vilela Teixeira, Duarte Mendes, Marco Araújo, Mariana Santos, Pedro Moutinho, Alexandra Costa-Duarte, et al.

    Background: Methocarbamol is a centrally acting skeletal muscle relaxant widely used for musculoskeletal pain associated with muscle spasm, despite an incompletely understood mechanism of action and uncertainty regarding its efficacy compared with placebo or other pharmacological interventions. Objective: To evaluate the efficacy of methocarbamol in reducing pain intensity in adults (≥18 years) with acute or chronic pain, compared with placebo or other pharmacological interventions, and to assess its impact on quality of life and other pain-related outcomes. Methods: This systematic review was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261440769). PubMed, Scopus, Web of Science, and Cochrane Library were searched from inception to 30 May 2026. Randomized and non-randomized controlled trials, cohort studies, case series, and narrative or systematic reviews reporting an extractable pain-related outcome were eligible. Risk of bias was assessed using RoB 2, ROBINS-I, or the Newcastle–Ottawa Scale, and level of evidence was graded per OCEBM 2011 criteria. Given substantial clinical and methodological heterogeneity, findings were synthesized narratively. Results: Twenty-eight studies (1959–2025; n = 30–9089), comprising 9 randomized controlled trials, 14 observational studies, 4 narrative/bibliographic reviews, and 1 case series, were included, spanning acute low back pain, postoperative/perioperative pain, trauma (including rib fractures), trigeminal neuralgia, cirrhosis-related muscle cramps, muscle strain, and opiate withdrawal. Results were inconsistent across indications: some trials showed benefit when methocarbamol was combined with NSAIDs or compared with opioids, while others—including the largest cohorts—found no advantage, partly attributable to confounding by indication. Opioid-sparing effects were observed in select postoperative and trauma populations. Methodological quality was generally moderate-to-high risk of bias. Conclusions: Evidence supporting methocarbamol’s analgesic efficacy is heterogeneous and inconclusive. Benefit appears most plausible in pain syndromes driven by muscle spasm, and it may have a role within multimodal, opioid-sparing strategies in selected postoperative and trauma settings. The available evidence is insufficient to support routine use across the clinical settings evaluated. Adequately powered, standardized randomized controlled trials are needed to clarify its true effect and identify patients most likely to benefit.

  • Open Access

    The Use of Benzodiazepines as an Adjuvant in Pain Management: A Narrative Review with Systematic Search

    by Alexandra da Costa-Duarte, Rita Rodrigues-Lopes, Ana Severino, Matilde Oliveira, Inês Guerra, Mariana Santos, Carolina Damas Pereira, Beatriz Sousa, Pedro Fernandes-Moutinho, Carolina Vilela Teixeira, et al.

    Background/objectives: Benzodiazepines are widely prescribed as adjuvants in pain management, particularly for musculoskeletal conditions, with prescription rates for back and chronic pain more than doubling between 2003 and 2015. Yet, the evidence supporting this practice remains poorly defined. This study evaluates the efficacy of benzodiazepines in pain management, analyzing comparative data, pharmacological mechanisms, and global clinical guidelines. Methods: Narrative review informed by a predefined systematic search of PubMed, Scopus, Cochrane Library and Web of Science. We searched for direct comparative studies between diazepam, alprazolam, and lorazepam in pain management identified no eligible studies, revealing a significant evidence gap despite decades of clinical use. This absence of comparative evidence prompted a broader narrative examination of the evidence base for benzodiazepines across pain conditions. Results: The available literature consistently fails to support benzodiazepine analgesia. Across 111 chronic pain conditions, analgesic benefit has been demonstrated for only two rare conditions: burning mouth syndrome (evidence primarily for topical clonazepam) and stiff person syndrome (primarily case series and clinical experience). In low back pain, the condition most associated with benzodiazepine prescribing, recent randomized trials show no benefit or even harm compared to placebo, and the only positive pooled evidence derived from trials of tetrazepam, a drug withdrawn from the European market in 2013. In rheumatoid arthritis, pooled data from six small trials show no benefit over placebo at any time point. The pharmacological basis for this clinical failure is now well characterized: conventional non-selective benzodiazepines produce dose-limiting sedation before achieving sufficient receptor occupancy at the α2/α3 GABA-A subtypes responsible for antihyperalgesic effects. Despite the lack of demonstrated efficacy, prescribing persists, likely driven by clinical inertia and patient expectations reflecting anxiolytic rather than analgesic properties. Guidelines from the WHO, NICE, the VA/DoD, the American College of Physicians, the American Academy of Family Physicians, and the Wilderness Medical Society uniformly recommend against benzodiazepine use for pain. This convergence of absent efficacy, well-documented harm, and unanimous guideline opposition supports the conclusion that benzodiazepines should not be prescribed as analgesic adjuvants. Conclusions: Although the focused search targeted head-to-head trials, a broader narrative synthesis and prior comprehensive reviews likewise demonstrate a paucity of high-quality evidence for benzodiazepine analgesia. Future research should focus on subtype-selective GABA-A modulators and on strategies to align clinical practice with the existing evidence, including structured deprescribing interventions.